For the year ending 2025-12-31, RPRX made $2,378,193K in revenue. $770,947K in net income. Net profit margin of 32.42%.
| Income Statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total income and other revenues | 2,378,193 | 2,263,576 | 2,354,554 | 2,237,215 |
| Provision for changes in expected cash flows from financial royalty assets | -295,838 | 732,461 | 560,656 | 904,244 |
| Provision for credit losses on unfunded commitments | 89,032 | - | - | - |
| Research and development funding expense | 452,000 | 2,000 | 52,000 | 177,106 |
| Amortization of intangible assets | - | 0 | 0 | 5,670 |
| General and administrative expenses (includes 290,890, 3,224, and 3,302 of share-based compensation expense for the years ended december 31, 2025, 2024 and 2023, respectively see note 4) | 573,481 | 236,671 | 249,748 | 227,303 |
| Financial royalty asset impairment | - | 0 | 0 | 615,827 |
| Total operating expense, net | 818,675 | 971,132 | 862,404 | 1,930,150 |
| Operating income | 1,559,518 | 1,292,444 | 1,492,150 | 307,065 |
| Equity in earnings of equity method investees | 29,089 | 29,611 | 28,882 | -8,973 |
| Interest expense | 307,664 | 225,512 | 187,187 | 187,961 |
| Losses on derivative financial instruments | 0 | -6,000 | -2,290 | 96,610 |
| Losses/(gains) on equity securities | -21,852 | 39,549 | 87,139 | -33,442 |
| Gains on available for sale debt securities | 45,859 | 154,906 | 230,840 | -6,815 |
| Interest income | 33,591 | 47,343 | 72,291 | 78,335 |
| Other non-operating expenses, net | -14,349 | -1,528 | -21,737 | -14,755 |
| Total other expense/(income), net | -235,326 | 38,369 | 207,938 | -77,001 |
| Consolidated net income before tax | 1,324,192 | 1,330,813 | 1,700,088 | 230,064 |
| Income tax expense | 0 | 0 | 0 | 0 |
| Consolidated net income | 1,324,192 | 1,330,813 | 1,700,088 | 230,064 |
| Net income attributable to non-controlling interests | 553,245 | 471,830 | 565,254 | 187,232 |
| Net income attributable to royalty pharma plc | 770,947 | 858,983 | 1,134,834 | 42,832 |
| Basic (in dollars per share) | 1.79 | 1.92 | 2.54 | 0.1 |
| Basic (in shares) | 429,801,000 | 448,185,000 | 447,601,000 | 437,963,000 |
| Diluted (in dollars per share) | 1.78 | 1.91 | 2.53 | 0.1 |
| Diluted (in shares) | 564,455,000 | 594,108,000 | 602,900,000 | 437,972,000 |
Royalty Pharma plc (RPRX)
Royalty Pharma plc (RPRX)